Publications

Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer Res Commun. 3(8):1447-1459.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 12(1):3372.

Berger A*, Brady NJ *, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 130:3924-3940.

Rickman DS, Schulte JH, Eilers M.  2018.  The Expanding World of N-MYC-Driven Tumors.. Cancer Discov. 8(2):150-163.

Büchel G, Carstensen A, Mak K-Y, Roeschert I, Leen E, Sumara O, Hofstetter J, Herold S, Kalb J, Baluapuri A et al..  2017.  Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.. Cell Rep. 21(12):3483-3497.

Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA et al..  2017.  A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.. Cold Spring Harb Mol Case Stud. 3(5)

Dhingra P, Martinez-Fundichely A, Berger A, Huang FW, Forbes ANeil, Liu EMinwei, Liu D, Sboner A, Tamayo P, Rickman DS et al..  2017.  Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.. Genome Biol. 18(1):141.

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 30(4):563-577.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JMiguel, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG et al..  2014.  ERG induces taxane resistance in castration-resistant prostate cancer.. Nat Commun. 5:5548.

Rickman DS, T Soong D, Moss B, Mosquera JMiguel, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V et al..  2012.  Oncogene-mediated alterations in chromatin conformation.. Proc Natl Acad Sci U S A. 109(23):9083-8.

Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.